Clinical Trial Detail

NCT ID NCT02219737
Title Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

Therapies

Ibrutinib

Carboplatin + Etoposide + Ifosfamide + Rituximab

Age Groups: adult

No variant requirements are available.